#### **National Center for Immunization & Respiratory Diseases**

**Centers for Disease Control and Prevention** 



# Nirsevimab: Implementation Considerations

#### Georgina Peacock, MD, MPH, FAAP

Director, Immunization Services Division

National Center for Immunization and Respiratory Diseases

Centers for Disease Control and Prevention (CDC)

#### **Implementation Considerations**

- Definition of Vaccine
- Cost
- Storage and Handling
- Hospital Dosing
- Outpatient Dosing
- Coding and Immunization Information Systems
- Timing of Vaccination
- 2<sup>nd</sup> Year Vaccinations
- Vaccine Administration
- Safety Reporting
- Vaccine Confidence and Demand



#### Definition of "Vaccine"

- No statutory definition of vaccine in the statute for the Vaccines for Children (VFC) program (section 1928 of the Social Security Act)
- No statutory definition of vaccine in the Affordable Care Act (section 2713 of PHS Act), or its implementing regulations, which has a provision that mandates coverage of vaccine recommendations included on CDC's immunization schedules
- CDC has determined that nirsevimab is eligible for inclusion in the childhood immunization schedule and Vaccines for Children program

#### Cost

- Cost of nirsevimab estimated at \$495 per dose in the private sector
- If recommended by ACIP, nirsevimab will be covered by insurance and included in the VFC program
  - Importance of ensuring equitable access to nirsevimab
- However, nirsevimab cost will still be a potential implementation barrier particularly for ambulatory practices
  - If nirsevimab included in VFC, practices must carry both VFC and private stock, which may be challenging for some practices

#### Nirsevimab Storage, Handling, and Administration

- Similar to other routine vaccines for children
- Administered as intramuscular injection using single-dose pre-filled syringe
  - Can be administered simultaneously with other childhood vaccines
- Dosed by weight/age
  - 50 mg if <5 kg</p>
  - o 100 mg if ≥5 kg
  - 200 mg (2x100 mg) for high-risk children entering 2<sup>nd</sup> RSV season
- Stored in refrigerator at 2-8° C
- May be kept at room temperature (20-25°C) for up to 8 hours



Source: California Department of Public Health

#### **Scope of Practice Issues**

 Jurisdictions may have different scope of practice statutes for who can administer injectable therapeutics vs. vaccines

- Scan of state laws indicates that most states allow medical assistants (who frequently administer vaccines) to also deliver injection drugs
  - However, organizations may have varied practices

#### **Hospital Administration**

- Approximately 10% of birthing hospitals participate in the VFC program
- Bundled payment model for newborn care
  - Hepatitis B vaccine more feasible to cover at ~\$13–16/dose
  - Will nirsevimab be included in bundled payments?
- Critical to ensure documentation of in-hospital nirsevimab administration in records sent to primary care provider
  - Potential challenges entering nirsevimab in the immunization information system (IIS)
  - Comprehensive maternal-neonatal records will become even more critical if maternal RSV vaccine is licensed and recommended


#### **Outpatient Administration**

- Communication from birthing hospital
- Communication about maternal RSV vaccine
- Initial investment by pediatricians unsure on price and demand for nirsevimab nor demand for new product
- Historical lag in insurance payment for new products

#### Coding

- CPT coding and AMA decision around CPT codes classified as a drug/therapeutic
- Administration codes do not include a counseling component
- Not eligible for stand-alone counseling
- Potential challenges with recording doses in Immunization Information Systems

## Preparing Systems for Administering a Newly Authorized <u>Vaccine</u> Across the U.S.



#### **IIS and Vaccine Forecasting Considerations**

- Nirsevimab coded as a therapeutic instead of vaccine could create challenges with:
  - Internal provider ordering
  - Provision of a vaccine record
  - Interoperability/data exchange with electronic health record (EHR) and IIS
- Forecasting (Clinical Decision-Support [CDS] for immunization)
  - Dosage by weight: CDS does not have access to patient weight
  - 2<sup>nd</sup> season recommendations
  - Future considerations: CDS systems unable to take into account maternal vaccination history for forecasting for infant nirsevimab immunization

#### **Special Considerations Add Complexity**

- Timing of vaccination based on RSV season
  - Tropical climates may have different/unpredictable seasonality when compared to most of continental U.S.
- Variability in different localities
  - For example, seasonality in AK less predictable and longer duration
- Second year dosing
  - High risk populations
  - Clarifying palivizumab recommendations in the setting of nirsevimab availability

#### Reporting of Adverse Events by Patients and Providers

- Reporting of suspected adverse events (AEs) more complicated for nirsevimab than other immunizations:
  - If nirsevimab is administered alone, suspected AEs are reported to MedWatch
  - If nirsevimab is administered simultaneously with any vaccine, suspected AEs are reported to the Vaccine Adverse Event Reporting System (VAERS); additional reporting to Medwatch not needed

### **Vaccine Confidence/Demand**

- Will physicians and public accept a new vaccine
- Occurring at the same time as commercialization of COVID-19 vaccine and seasonal influenza administration
- Vaccine hesitancy and anticipated need for counseling around all vaccines and products
- Efforts to weaken school immunization requirements and expand vaccine exemptions at the state level

#### **Conclusion and Discussion**

- Considerations for implementation
- Risks during this season's roll out
  - Timing of availability of doses
  - Provider hesitancy
  - Uptake
- Complexity of recommendations
  - Hospital vs. Outpatient
  - Seasonality / Timing
  - Lessons learned with Hepatitis A and B
- Unintended consequences

### Thank You!

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

